AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Neurocrine Biosciences, Inc.
Video analysis: NBIX
All videosNo video analysis for this stock yet. Request one from our team.
News: NBIX
Amundi Has $37.16 Million Position in Neurocrine Biosciences, Inc. $NBIX
Amundi lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 8.3% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 220,463 shares of the company's stock after purchasing an additional 16,826 shares during the quarter. Amundi owned 0.22% of
Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Continuum Advisory LLC
Continuum Advisory LLC decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 99.1% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 418 shares of the company's stock after selling 43,650 shares during the period. Continuum Advisory LLC's holdings in Neurocrine Biosciences were
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21 st Annual Healthcare Conference.
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
B. Metzler seel. Sohn & Co. AG Acquires New Shares in Neurocrine Biosciences, Inc. $NBIX
B. Metzler seel. Sohn and Co. AG acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 5,986 shares of the company's stock, valued at approximately $1,009,000. Other institutional investors and hedge
Similar companies
-
The Cooper Companies, Inc.
COO
·
NASDAQ
Compare
-
Elanco Animal Health Incorporated
ELAN
·
New York Stock Exchange
Compare
-
Viatris Inc.
VTRS
·
NASDAQ
Compare
-
Dr. Reddy's Laboratories Limited
RDY
·
New York Stock Exchange
Compare
-
ICON Public Limited Company
ICLR
·
NASDAQ
Compare
-
Universal Health Services, Inc.
UHS
·
New York Stock Exchange
Compare